NCT02387957View on ClinicalTrials.gov

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

PHASE2TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 26, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Fovista®

DRUG

bevacizumab

DRUG

ranibizumab

DRUG

aflibercept

Trial Locations (24)

14620

Rochester

19006

Huntingdon Valley

26506

Morgantown

29456

Ladson

30909

Augusta

33308

Fort Lauderdale

33912

Fort Myers

44130

Cleveland

48034

Southfield

55435

Minneapolis

60452

Oak Forest

77384

The Woodlands

78240

San Antonio

79106

Amarillo

85014

Phoenix

Abilene

89502

Reno

90211

Beverly Hills

92705

Santa Ana

95819

Sacramento

98383

Silverdale

06320

New London

02114

Boston

01605

Worcester

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT02387957 - A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) | Biotech Hunter | Biotech Hunter